For the year ended August 31, 2019, the segment incurred $7,423,540 in operating expenses. Included in operating expenses was: The segment operating loss of $7,423,540 is a result of the Company …

More Cannara Biotech Reports Q4 and Year-End 2019 Financial Results Videos